Sandip Kapadia Sells 1,775 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Stock

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) CFO Sandip Kapadia sold 1,775 shares of the firm’s stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $38.05, for a total value of $67,538.75. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Sandip Kapadia also recently made the following trade(s):

• On Tuesday, January 21st, Sandip Kapadia sold 25,000 shares of Harmony Biosciences stock. The shares were sold at an average price of $40.18, for a total value of $1,004,500.00.

Harmony Biosciences Trading Up 0.4 %

Shares of HRMY traded up $0.17 during trading hours on Tuesday, reaching $38.42. 519,661 shares of the company traded hands, compared to its average volume of 579,787. Harmony Biosciences Holdings, Inc. has a 12 month low of $28.14 and a 12 month high of $41.61. The company has a market capitalization of $2.19 billion, a price-to-earnings ratio of 18.21, a price-to-earnings-growth ratio of 0.51 and a beta of 0.78. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28. The company’s fifty day moving average price is $34.86 and its two-hundred day moving average price is $35.12.

Harmony Biosciences (NASDAQ:HRMY) last announced its earnings results on Tuesday, October 29th. The company reported $0.79 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.15. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The business had revenue of $186.00 million during the quarter, compared to the consensus estimate of $184.07 million. During the same quarter last year, the firm earned $0.63 earnings per share. The business’s revenue for the quarter was up 16.0% on a year-over-year basis. Equities research analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Pacer Advisors Inc. raised its holdings in Harmony Biosciences by 18.2% in the 4th quarter. Pacer Advisors Inc. now owns 2,279,918 shares of the company’s stock worth $78,452,000 after acquiring an additional 351,582 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Harmony Biosciences by 13.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 956,785 shares of the company’s stock worth $28,871,000 after purchasing an additional 112,197 shares in the last quarter. Massachusetts Financial Services Co. MA raised its stake in shares of Harmony Biosciences by 27.1% in the third quarter. Massachusetts Financial Services Co. MA now owns 660,391 shares of the company’s stock worth $26,416,000 after purchasing an additional 140,690 shares during the last quarter. Millennium Management LLC lifted its holdings in shares of Harmony Biosciences by 51.6% during the second quarter. Millennium Management LLC now owns 307,420 shares of the company’s stock valued at $9,275,000 after purchasing an additional 104,691 shares in the last quarter. Finally, Marshall Wace LLP boosted its position in shares of Harmony Biosciences by 145.4% during the second quarter. Marshall Wace LLP now owns 305,612 shares of the company’s stock valued at $9,220,000 after buying an additional 181,092 shares during the last quarter. Institutional investors own 86.23% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on HRMY. Oppenheimer reaffirmed an “outperform” rating and issued a $59.00 target price (up previously from $56.00) on shares of Harmony Biosciences in a research note on Wednesday, October 30th. Raymond James reaffirmed an “outperform” rating and issued a $40.00 price objective on shares of Harmony Biosciences in a research note on Thursday, October 10th. Mizuho lifted their target price on shares of Harmony Biosciences from $42.00 to $52.00 and gave the stock an “outperform” rating in a research report on Thursday, October 10th. Needham & Company LLC restated a “buy” rating and set a $52.00 price target on shares of Harmony Biosciences in a research report on Monday, January 13th. Finally, Cantor Fitzgerald lifted their price objective on Harmony Biosciences from $51.00 to $58.00 and gave the stock an “overweight” rating in a report on Wednesday, October 30th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Harmony Biosciences presently has a consensus rating of “Buy” and a consensus target price of $55.00.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.